263
Participants
Start Date
January 4, 2016
Primary Completion Date
September 4, 2016
Study Completion Date
September 5, 2016
insulin degludec/insulin aspart
Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
biphasic insulin aspart
Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
Novo Nordisk Investigational Site, Umm Al Quwain City
Novo Nordisk Investigational Site, Benoni
Novo Nordisk Investigational Site, Johannesburg
Novo Nordisk Investigational Site, Johannesburg
Novo Nordisk Investigational Site, Lenasia
Novo Nordisk Investigational Site, Durban
Novo Nordisk Investigational Site, Durban
Novo Nordisk Investigational Site, Ajman
Novo Nordisk Investigational Site, Durban
Novo Nordisk Investigational Site, Dubai
Novo Nordisk Investigational Site, Cape Town
Novo Nordisk Investigational Site, Lebanon - Beirut
Novo Nordisk Investigational Site, Kota Bharu, Kelantan
Novo Nordisk Investigational Site, Sétif
Novo Nordisk Investigational Site, Ajman
Novo Nordisk Investigational Site, Sidi Bel Abbes
Novo Nordisk Investigational Site, Oran
Novo Nordisk Investigational Site, Cheras
Novo Nordisk Investigational Site, Seremban, Negeri Sembilan
Novo Nordisk Investigational Site, New Delhi
Novo Nordisk Investigational Site, Mumbai
Novo Nordisk Investigational Site, Mumbai
Novo Nordisk Investigational Site, Pune
Novo Nordisk Investigational Site, Hyderabad
Novo Nordisk Investigational Site, Mysore
Novo Nordisk Investigational Site, Kozhikode
Novo Nordisk Investigational Site, Kolkata
Novo Nordisk Investigational Site, Algiers
Novo Nordisk Investigational Site, Beirut
Novo Nordisk Investigational Site, Hazmiyeh
Novo Nordisk Investigational Site, Hyderabad
Novo Nordisk Investigational Site, Pretoria
Lead Sponsor
Novo Nordisk A/S
INDUSTRY